These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

771 related articles for article (PubMed ID: 27746366)

  • 1. MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway.
    Shen H; Wang D; Li L; Yang S; Chen X; Zhou S; Zhong S; Zhao J; Tang J
    Gene; 2017 Jan; 596():110-118. PubMed ID: 27746366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-222 induces Adriamycin resistance in breast cancer through PTEN/Akt/p27
    Wang DD; Yang SJ; Chen X; Shen HY; Luo LJ; Zhang XH; Zhong SL; Zhao JH; Tang JH
    Tumour Biol; 2016 Nov; 37(11):15315-15324. PubMed ID: 27699665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-29a contributes to drug-resistance of breast cancer cells to adriamycin through PTEN/AKT/GSK3β signaling pathway.
    Shen H; Li L; Yang S; Wang D; Zhong S; Zhao J; Tang J
    Gene; 2016 Nov; 593(1):84-90. PubMed ID: 27523474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling.
    Chen Y; Sun Y; Chen L; Xu X; Zhang X; Wang B; Min L; Liu W
    Mol Med Rep; 2013 May; 7(5):1579-84. PubMed ID: 23546450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN.
    Wang ZX; Lu BB; Wang H; Cheng ZX; Yin YM
    Arch Med Res; 2011 May; 42(4):281-90. PubMed ID: 21820606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-κB signaling pathway in breast cancer.
    Xie M; Fu Z; Cao J; Liu Y; Wu J; Li Q; Chen Y
    Biomed Pharmacother; 2018 Jun; 102():286-294. PubMed ID: 29567542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells.
    Zhong S; Li W; Chen Z; Xu J; Zhao J
    Gene; 2013 Nov; 531(1):8-14. PubMed ID: 23994196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of microRNA-181a may suppress proliferation and invasion and promote apoptosis of cervical cancer cells through the PTEN/Akt/FOXO1 pathway.
    Xu H; Zhu J; Hu C; Song H; Li Y
    J Physiol Biochem; 2016 Dec; 72(4):721-732. PubMed ID: 27534652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-222 confers the resistance of breast cancer cells to Adriamycin through suppression of p27(kip1) expression.
    Wang DD; Li J; Sha HH; Chen X; Yang SJ; Shen HY; Zhong SL; Zhao JH; Tang JH
    Gene; 2016 Sep; 590(1):44-50. PubMed ID: 27282281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-221 promotes breast cancer resistance to adriamycin via modulation of PTEN/Akt/mTOR signaling.
    Yin Y; Wang X; Li T; Ren Q; Li L; Sun X; Zhang B; Wang X; Han H; He Y; Cao Z; Sun X; Zhou Z
    Cancer Med; 2020 Feb; 9(4):1544-1552. PubMed ID: 31899608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-130b targets PTEN to mediate drug resistance and proliferation of breast cancer cells via the PI3K/Akt signaling pathway.
    Miao Y; Zheng W; Li N; Su Z; Zhao L; Zhou H; Jia L
    Sci Rep; 2017 Feb; 7():41942. PubMed ID: 28165066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomal curcumin alters chemosensitivity of breast cancer cells to Adriamycin via regulating microRNA expression.
    Zhou S; Li J; Xu H; Zhang S; Chen X; Chen W; Yang S; Zhong S; Zhao J; Tang J
    Gene; 2017 Jul; 622():1-12. PubMed ID: 28431975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss.
    Zhong T; Xu F; Xu J; Liu L; Chen Y
    Biomed Pharmacother; 2015 Feb; 69():317-25. PubMed ID: 25661377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional screen analysis reveals miR-3142 as central regulator in chemoresistance and proliferation through activation of the PTEN-AKT pathway in CML.
    Zhao L; Shan Y; Liu B; Li Y; Jia L
    Cell Death Dis; 2017 May; 8(5):e2830. PubMed ID: 28542127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of miR-7 on resistance of breast cancer cells to adriamycin via regulating EGFR/PI3K signaling pathway.
    Huang Q; Wu YY; Xing SJ; Yu ZW
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5285-5292. PubMed ID: 31298380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of miR-195 increases the sensitivity of breast cancer cells to Adriamycin treatment through inhibition of Raf-1.
    Yang G; Wu D; Zhu J; Jiang O; Shi Q; Tian J; Weng Y
    Oncol Rep; 2013 Aug; 30(2):877-89. PubMed ID: 23760062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β-Elemene Reverses Chemoresistance of Breast Cancer Cells by Reducing Resistance Transmission via Exosomes.
    Zhang J; Zhang HD; Yao YF; Zhong SL; Zhao JH; Tang JH
    Cell Physiol Biochem; 2015; 36(6):2274-86. PubMed ID: 26279432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTENP1/miR-20a/PTEN axis contributes to breast cancer progression by regulating PTEN via PI3K/AKT pathway.
    Gao X; Qin T; Mao J; Zhang J; Fan S; Lu Y; Sun Z; Zhang Q; Song B; Li L
    J Exp Clin Cancer Res; 2019 Jun; 38(1):256. PubMed ID: 31196157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic analysis of gene expression pattern in has-miR-760 overexpressed resistance of the MCF-7 human breast cancer cell to doxorubicin.
    Lv J; Fu Z; Shi M; Xia K; Ji C; Xu P; Lv M; Pan B; Dai L; Xie H
    Biomed Pharmacother; 2015 Feb; 69():162-9. PubMed ID: 25661353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
    Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
    Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.